Shares of Boston Scientific (NYSE:BSX) are enjoying a modest gain today after Moody’s Investors Service (NYSE:MCO) upgraded its debt rating.
Intuitive Surgical
St. Jude lands FDA win for 2 next-gen cardiac ablation catheters | Regulatory Roundup
St. Jude Medical Inc. (NYSE:STJ) won pre-market approval for 2 next-generation cardiac ablation systems this month, the Therapy Cool Path Duo and Safire Blu Duo catheters.
Both ablation systems use radiofrequency energy to freeze small areas of faulty cardiac tissue in patients with typical trial flutter, a type of arrhythmia in which patients experience abnormal heart rhythms or an abnormally fast heartbeat in the upper chambers of the heart.
Boston Scientific to hit the acquisitions trail | Wall Street Beat
Boston Scientific (NYSE:BSX) plans to hoard most of the more than $1 billion in free cash flow it expects to generate this year so it can make acquisitions to boost its top line, CFO Jeff Capello told analysts last week.
VC spend in life sciences grew in 2011 | Wall Street Beat
Venture capital funding of life science startups, including biotech and medical device enterprises, rose by 21% last year, according to PricewaterhouseCoopers.
VCs dropped $7.5 billion on 785 life sciences deals during the year, according to a PwC report, "Zigzagging Upward," compiled using data from the PricewaterhouseCoopers LLP/National Venture Capital Assn. MoneyTree Report and Thomson Reuters.
AngioDynamics CEO: Navilyst deal hits the reset button | Wall Street Beat
Updated February 1, 2012 at 5:30 p.m.
The $372 million buyout of Navilyst Medical by AngioDynamics (NSDQ:ANGO) is a reset button that will reinforce the combined operation for the future, AngioDynamics CEO Joe DeVivo told MassDevice this afternoon.
Is robotic surgery worth the price? | MassDevice.com On Call
MASSDEVICE ON CALL — Complication rates for women with endometrial cancer were roughly the same after standard laparoscopy and robot-assisted surgery, although the robotic procedures each cost about $1,300 more, according to a study in the Journal of Clinical Oncology.
J&J CEO Weldon: Medical sales slump has bottomed out | Wall Street Beat
The sales slump endured by the medical industry as the economic crisis hit may be over, according to Johnson & Johnson CEO William Weldon.
That means procedure volumes for elective surgeries could rebound, Weldon told Bloomberg after the company released its financial results for the 4th quarter and 2011.
Intuitive Surgical’s 2011 beats The Street, but shares slide on decelerating growth
Intuitive Surgical (NSDQ:ISRG) posted a Street-beating 4th quarter, the surgical robot maker’s shares still slid on slower procedure growth.
The Sunnyvale, Calif.-based company posted $1.76 billion in sales during 2011, a 24% spike compared with 2010, placing 534 da Vinci robot-assisted surgery systems during the year – a 21.1% increase.
VC investment slows in Q4 but still beats 2010 | Wall Street Beat
Venture capitalists poured $6.57 billion into 884 deals during the 4th quarter, down compared with Q3 but up 19% compared with Q4 2010, according to the MoneyTree report.
Goldman pans Wall Street’s med-tech estimates
Wall Street’s overall take on sales and earnings forecasts for medical device makers this year is too high, according to Goldman Sachs (NYSE:GS) analyst David Roman, who sees The Street’s 4th-quarter top-line estimates as split evenly among companies with upside and downside.
Electromed: Q2, H2 2012 sales, earnings growth to slow | Wall Street Beat
Electromed (NSDQ:ELMD) CEO Robert Hansen said the company expects its sales and earnings numbers to slide for the 2nd quarter and 2nd half of 2012, after a sales force restructuring hit its top line.